原发性胆汁性胆管炎患者的肝外自身免疫病:全国性发生情况及与结局的关系
该回顾性全国队列研究纳入荷兰1990至2023年4351例原发性胆汁性胆管炎(PBC)患者,27.3%诊断有肝外自身免疫病(EHAID),最常见为甲状腺功能减退症(35.6%)和干燥综合征(18.3%)。
要点
- PBC患者中EHAID常见,27.3%至少合并一种,以甲状腺功能减退症和干燥综合征为主。
- EHAID多在PBC基线时即存在(80.7%),提示需在初诊时系统筛查。
- EHAID与无肝移植生存及肝病进展无显著关联,不改变PBC长期预后。
核心结论
- 在全国PBC人群中EHAID常见且多在基线时存在,但EHAID与长期临床结局(无肝移植生存、肝病进展)无显著关联。
研究设计与样本
- 回顾性荷兰PBC全国队列研究,纳入1990至2023年荷兰所有可识别的PBC患者,共4351例,采用生存分析评估EHAID与无肝移植生存及肝病进展的关联。
主要发现
- 4351例中1186例(27.3%)诊断有EHAID,最常见为甲状腺功能减退症(35.6%),其次为干燥综合征(18.3%)。
- EHAID在基线时即存在者957例(80.7%)。
- 基线有EHAID者女性比例更高(92.1% vs 87.0%,P<.001),肝硬化比例更低(5.4% vs 7.3%,P=.046),γ-谷氨酰转移酶水平更低(5.79倍正常上限 vs 6.55倍正常上限,P<.001)。
- 基线有EHAID者10年无肝移植生存率为83.3%(95%CI 81.8%-84.9%),无EHAID者为84.6%(95%CI 81.8%-87.6%),P=.378。
- 多变量分析中EHAID与无肝移植生存(调整HR 0.81,95%CI 0.63-1.05,P=.121)及肝病进展(调整HR 0.92,95%CI 0.65-1.32,P=.662)均无显著关联。
临床怎么用
- 在PBC初诊时系统评估EHAID,因多数EHAID在基线时已存在且可能解释或加重PBC症状。
- EHAID的存在不改变对PBC长期预后的判断,但仍需针对EHAID进行相应管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Primary biliary cholangitis (PBC) is associated with several extrahepatic autoimmune diseases (EHAIDs), but reliable prevalence estimates are scarce. We determined the occurrence of EHAIDs in a nationwide population with PBC and the association with outcomes. METHODS: The retrospective Dutch PBC Cohort Study includes every identifiable person with PBC in the Netherlands from 1990 up to 2023. Survival analyses were used to assess whether EHAID is associated with liver transplant (LT)-free survival or liver disease progression. RESULTS: In total, 4351 individuals were included, of whom 1186 (27.3%) were diagnosed with EHAIDs. Hypothyroidism was the most common EHAID (35.6%), followed by Sjögren's syndrome (18.3%). EHAIDs were present at baseline in 957 cases (80.7%). At baseline, people with EHAIDs were more frequently female (92.1% vs 87.0%; P < .001), had cirrhosis less frequently (5.4% vs 7.3%; P = .046), and had lower γ-glutamyltransferase levels (5.79 × upper limit of normal vs 6.55 × upper limit of normal; P < .001). The 10-year LT-free survival was 83.3% (95% confidence interval [CI], 81.8%-84.9%) among those with EHAID at baseline vs 84.6% (95% CI, 81.8%-87.6%) among those without (P = .378). The absent association between EHAID and outcomes remained in multivariable analyses (adjusted hazard ratio, 0.81; 95% CI, 0.63-1.05; P = .121 for LT-free survival and adjusted hazard ratio, 0.92; 95% CI, 0.65-1.32; P = .662 for liver disease progression). CONCLUSIONS: In a nationwide population of individuals with PBC, EHAIDs are common. EHAIDs were mostly present at baseline and were not associated with long-term clinical outcomes. As symptoms in people with PBC may be aggregated or caused by concurrent EHAIDs, this study is important to improve the awareness and evaluation of EHAIDs in PBC.
引用
- Weijsters GHX, Werner E, Blom T, et al. Extrahepatic Autoimmune Disease in People With Primary Biliary Cholangitis: Nationwide Occurrence and Relation to Outcome. Clin Gastroenterol Hepatol. 2026. PMID: 42790837. doi:10.1016/j.cgh.2026.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。